– Pipeline strengthens with addition of AM-125 as third clinical-stage program
– Acquisition of assets related to innovative betahistine product for intranasal delivery
– Betahistine is one of the most widely used treatments for vestibular disorders
– Conference call and webcast scheduled for today at 8 am Eastern Time
ZUG, Switzerland, Feb. 3, 2017 (GLOBE NEWSWIRE) — Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it has added a third clinical-stage development program to its pipeline and is expanding into the field of vestibular disorders. Under the product code AM-125, the Company will develop betahistine dihydrochloride in a spray formulation for the intranasal treatment of Meniere’s disease and vestibular vertigo.